Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab

Abstract

Abstract. The present study aimed to determine whether nimotuzumab enhances the effect of radiochemotherapy in malignant gliomas. Patients (n=41) with malignant gliomas were divided into 20 cases (treatment group) in which nimotuzumab plus radiochemotherapy were offered and 21 cases (control group) in which placebo and radiochemotherapy were administered to the patients. The response to treatment was evaluated according to the Response Evaluation Criteria in Solid Tumors, the Kaplan-Meier method was used to calculate the mean and median survival times and 1-year survival rate, and the log-rank test and the Chi-square test were used to analyze the difference in the survival and response rate between the treatment and control groups. The mean survival times of the treatment and control groups were 14.3 and 10.4 months and the median survival times of the treatment and control groups were 16.5 and 10.5 months, respectively. The 1-year survival rates of the treatment and control groups were 81.3 and 69.1%, respectively, with no significant difference (P>0.05). The objective response rates of the treatment and control groups were 70.0 and 52.4%, respectively, with no significant difference (P>0.05). In conclusion, there was a trend towards improved treatment efficacy of radiochemotherapy combined with nimotuzumab against malignant gliomas. This study demonstrated that the use of nimotuzumab combined with radiotherapy and concomitant temozolomide chemotherapy is effective for malignant gliomas.

The Epidemiological Characteristics and Prognostic Factors of Low-Grade Brainstem Glioma: A Real-World Study of Pediatric and Adult Patients

“…Indeed, no CT regimen has been proven to be effective for LGBSG patients. Only few cases were reported to have a good response to CT (14,27,28). In addition, the Kaplan-Meier curves plotted both in all patients (n = 305) and non-GTR group (n = 125) supported that adjuvant therapy provided no clinical benefits.…”

Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities

“…A Phase I/II trial evaluated whether nimotuzumab enhanced the effect of radiochemotherapy in HGG (Table 1). 40 A total of 41 patients were randomized to receive 6 weekly infusions of nimotuzumab (200 mg), or placebo in addition to radiotherapy (46–66 Gy) and a temozolomide based regime. Temozolomide was administered daily (75 mg/m2) during radiation therapy.…”

Nimotuzumab in Management of Brain Stem Glioma: A Case Report

“…In our patient after treatment of TMZ (three cycles of 250 mg once in a day for 5 days) patient pro-gressed with disease as seen by worsening of symptoms and increase in the size of tumour. The probable reason for lack of effectiveness to TMZ could be the presence of high MGMT activity [10].…”

“…Hong et al reported that Nimotuzumab is effective in improving the response rate or the survival time when it is used with or without radiotherapy; chemotherapy in high-grade glioma [10]. Westphal et al in a phase III study also assessed the efficacy of Nimotuzumab using a higher doses and found progression free survival rate (PFS) and overall survival (OS) at 12 months higher in a group of subjects treated for 12 consecutive a weekly infusions of 400 mg of nimotuzumab during standard radiotherapy along with temozolomide followed by biweekly infusions of 400 mg (PFS = 25.5%, OS = 679 days) than the group of subjects treated with standard radio and chemotherapy alone (PFS = 20.3%, OS = 596 days).…”